COMMUNIQUÉS West-GlobeNewswire

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
10/09/2025
BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has made an [...]
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
10/09/2025
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability Highly encouraging initial clinical results for [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/09/2025
PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that the [...]
Design Therapeutics Appoints Justin Gover to Board of Directors
10/09/2025
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the [...]
Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
10/09/2025
The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a [...]
IBA – TRANSPARENCY NOTIFICATION
10/09/2025
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, September 10, 2025 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
IBA SA – NOTIFICATION TRANSPARENCE
10/09/2025
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 10 septembre 2025, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), [...]
Dewpoint Therapeutics Closes Series D Financing to Advance First-in-Class Condensate Modulator (c-mod) into Clinical Development for Gastric Cancer
10/09/2025
Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer. Strong support from leading investors and global pharma partners continues to validate the innovative [...]
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
10/09/2025
WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will [...]
BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.
10/09/2025
Strategic Rebranding to Focus on Expanded Business Model and Growth Strategy. New Ticker Symbol “STEX”. LOS ANGELES & VANCOUVER, British Columbia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ [...]
Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025
10/09/2025
Allschwil, Switzerland – September 10, 2025 Idorsia Ltd (SIX: IDIA) shares new analyses of daridorexant for patients with insomnia and further characterizes insomnia disorder at World Sleep 2025, delivering on its [...]
Tecan announces change of leadership in the Partnering Business division
10/09/2025
Männedorf, Switzerland, September 10, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today announced a change of leadership in its Partnering Business division. Ralf Griebel, who has served as Head of the Partnering [...]
Marius Pharmaceuticals and Hims & Hers™ Collaborate to Expand Access to KYZATREX® (testosterone undecanoate) CIII Capsules, the First FDA-Approved Oral Testosterone Therapy Offered on the Hims & Hers Platform
10/09/2025
RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™ , one of the largest digital health platforms for men, to make KYZATREX ® , an FDA- [...]
Partnership between Corewell Health and Nudj Health drives progress in chronic condition management
10/09/2025
The model is making lasting improvements to thousands of patients who have a broad spectrum of chronic conditions AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Corewell Health ™ patients who used virtual lifestyle [...]
Johns Hopkins Health Plans Opens 2026 Grant Application Period
10/09/2025
Baltimore-Washington Region Nonprofits Invited to Apply for Grants Up to $20,000 HANOVER, Md., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Johns Hopkins Health Plans has launched the grant application period for its 2026 [...]
Realize Medical and Canon USA Partner to Redefine Procedural Planning Through Spatial Computing with VR and Imaging Technology
10/09/2025
Collaboration aims to create the lab of the future, enabling safer, faster, and more precise interventions Key Benefits of Partnership Integration of VR and imaging: Combines Realize Medical’s VR platform with Canon’s [...]
Trethera Successfully Completes Enrollment of Phase 1 Dose Escalation Trial for Patients with Solid Tumors
10/09/2025
LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that [...]
Une plateforme néerlandaise rend les soins dermatologiques instantanément accessibles dans le monde entier
10/09/2025
Dermatology2Go se focalise sur les soins de la peau en ligne, sans temps d’attente et avec des informations fiables BERGEN OP ZOOM, Pays-Bas, 10 sept. 2025 (GLOBE NEWSWIRE) -- Une nouvelle plateforme néerlandaise a été [...]
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer’s Disease Program
10/09/2025
The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling program for the NN-840 program with an IND submission expected next year This NIH grant award strongly confirms the scientific and [...]

Pages